Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Regeneron Pharmaceuticals, Inc.

NASDAQ

Market Cap.

106.74B

Avg. Volume

447.49K

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Regeneron Pharmaceuticals, Inc.!

Still processing it, give me a bit more time...

Regeneron Pharmaceuticals, Inc. News

Regeneron Pharmaceuticals, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareBiotechnology
regeneron.com

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. Earnings & Revenue

Regeneron Pharmaceuticals, Inc. Financials

Table Compare

Compare REGN metrics with:

   

Earnings & Growth

REGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

REGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

REGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

REGN

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Regeneron Pharmaceuticals, Inc. Income

Regeneron Pharmaceuticals, Inc. Balance Sheet

Regeneron Pharmaceuticals, Inc. Cash Flow

Regeneron Pharmaceuticals, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Buy
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Regeneron Pharmaceuticals, Inc. Executives

NameRole
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, Chief Executive Officer & Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman
Mr. Daniel P. Van PlewExecutive Vice President and GM of Industrial Operations & Product Supply
Mr. Joseph J. LaRosaExecutive Vice President, General Counsel & Secretary
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research
NameRoleGenderDate of BirthPay
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, Chief Executive Officer & Co-Chairman19538.18M
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman19607.76M
Mr. Daniel P. Van PlewExecutive Vice President and GM of Industrial Operations & Product SupplyMale19732.01M
Mr. Joseph J. LaRosaExecutive Vice President, General Counsel & SecretaryMale19591.75M
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research19591.68M

Regeneron Pharmaceuticals, Inc. Insider Trades

Date21 May
NameLAROSA JOSEPH J
RoleEVP General Counsel and Secret
TransactionDisposed
TypeS-Sale
Shares1865
Date17 May
NameSCHLEIFER LEONARD S
RoleBd. Co-Chair, President & CEO
TransactionDisposed
TypeS-Sale
Shares22687
Date17 May
NameSCHLEIFER LEONARD S
RoleBd. Co-Chair, President & CEO
TransactionDisposed
TypeS-Sale
Shares143
Date16 May
NameYANCOPOULOS GEORGE
RoleBd. Co-Chair, President & CSO
TransactionDisposed
TypeS-Sale
Shares907
Date16 May
NameYANCOPOULOS GEORGE
RoleBd. Co-Chair, President & CSO
TransactionDisposed
TypeS-Sale
Shares3213
DateNameRoleTransactionTypeShares
21 MayLAROSA JOSEPH JEVP General Counsel and SecretDisposedS-Sale1865
17 MaySCHLEIFER LEONARD SBd. Co-Chair, President & CEODisposedS-Sale22687
17 MaySCHLEIFER LEONARD SBd. Co-Chair, President & CEODisposedS-Sale143
16 MayYANCOPOULOS GEORGEBd. Co-Chair, President & CSODisposedS-Sale907
16 MayYANCOPOULOS GEORGEBd. Co-Chair, President & CSODisposedS-Sale3213

Discover More

Streamlined Academy

Regeneron Pharmaceuticals, Inc.

NASDAQ

Market Cap.

106.74B

Avg. Volume

447.49K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Regeneron Pharmaceuticals, Inc. News

Regeneron Pharmaceuticals, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Regeneron Pharmaceuticals, Inc. Earnings & Revenue

Regeneron Pharmaceuticals, Inc. Income

Regeneron Pharmaceuticals, Inc. Balance Sheet

Regeneron Pharmaceuticals, Inc. Cash Flow

Regeneron Pharmaceuticals, Inc. Financials Over Time

Regeneron Pharmaceuticals, Inc. Executives

NameRole
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, Chief Executive Officer & Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman
Mr. Daniel P. Van PlewExecutive Vice President and GM of Industrial Operations & Product Supply
Mr. Joseph J. LaRosaExecutive Vice President, General Counsel & Secretary
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research
NameRoleGenderDate of BirthPay
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, Chief Executive Officer & Co-Chairman19538.18M
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman19607.76M
Mr. Daniel P. Van PlewExecutive Vice President and GM of Industrial Operations & Product SupplyMale19732.01M
Mr. Joseph J. LaRosaExecutive Vice President, General Counsel & SecretaryMale19591.75M
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research19591.68M

Regeneron Pharmaceuticals, Inc. Insider Trades

Date21 May
NameLAROSA JOSEPH J
RoleEVP General Counsel and Secret
TransactionDisposed
TypeS-Sale
Shares1865
Date17 May
NameSCHLEIFER LEONARD S
RoleBd. Co-Chair, President & CEO
TransactionDisposed
TypeS-Sale
Shares22687
Date17 May
NameSCHLEIFER LEONARD S
RoleBd. Co-Chair, President & CEO
TransactionDisposed
TypeS-Sale
Shares143
Date16 May
NameYANCOPOULOS GEORGE
RoleBd. Co-Chair, President & CSO
TransactionDisposed
TypeS-Sale
Shares907
Date16 May
NameYANCOPOULOS GEORGE
RoleBd. Co-Chair, President & CSO
TransactionDisposed
TypeS-Sale
Shares3213
DateNameRoleTransactionTypeShares
21 MayLAROSA JOSEPH JEVP General Counsel and SecretDisposedS-Sale1865
17 MaySCHLEIFER LEONARD SBd. Co-Chair, President & CEODisposedS-Sale22687
17 MaySCHLEIFER LEONARD SBd. Co-Chair, President & CEODisposedS-Sale143
16 MayYANCOPOULOS GEORGEBd. Co-Chair, President & CSODisposedS-Sale907
16 MayYANCOPOULOS GEORGEBd. Co-Chair, President & CSODisposedS-Sale3213

Streamlined Academy

Website screenshot
HealthcareBiotechnology
regeneron.com

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Regeneron Pharmaceuticals, Inc.!

Still processing it, give me a bit more time...

Regeneron Pharmaceuticals, Inc. Financials

Table Compare

Compare REGN metrics with:

   

Earnings & Growth

REGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

REGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

REGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

REGN

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Regeneron Pharmaceuticals, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Buy
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More